| Mark Tyson Garon, MD | |
|
7301 Hennessy Blvd Ste 200, Department Of Orthopedics, Baton Rouge, LA 70808-4794 | |
| (225) 766-0050 | |
| (225) 766-1499 |
| Full Name | Mark Tyson Garon |
|---|---|
| Gender | Male |
| Speciality | Hand Surgery |
| Experience | 14 Years |
| Location | 7301 Hennessy Blvd Ste 200, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376860148 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Our Lady Of The Lake Regional Medical Center | Baton rouge, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bone And Joint Clinic Of Baton Rouge, Inc A Professional Medical Corp | 3779478615 | 41 |
News Archive
Talecris Biotherapeutics announced today the Canadian launch of PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human])(A1PI), a more concentrated and purified formulation of PROLASTIN®, the only approved alpha1-augmentation therapy in Canada for more than 20 years. PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting the infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min.
RNA encodes the proteins that play a key role in cellular reproduction, but the manner in which cells regulate its removal once these proteins are synthesized remains a mystery. One piece of this mystery has been solved as researchers at the University of North Carolina at Chapel Hill who have identified the steps by which a cell removes RNA from the cytoplasm.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
Cardiovascular disease is the leading cause of death globally and a tremendous burden on the healthcare system. Better detection of hardening or clogging of arteries and other blood vessels before symptoms occur is needed.
› Verified 3 days ago
| Entity Name | Concordia Parish Hospital Service District Number One |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952565335 PECOS PAC ID: 4587559935 Enrollment ID: O20041012000111 |
News Archive
Talecris Biotherapeutics announced today the Canadian launch of PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human])(A1PI), a more concentrated and purified formulation of PROLASTIN®, the only approved alpha1-augmentation therapy in Canada for more than 20 years. PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting the infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min.
RNA encodes the proteins that play a key role in cellular reproduction, but the manner in which cells regulate its removal once these proteins are synthesized remains a mystery. One piece of this mystery has been solved as researchers at the University of North Carolina at Chapel Hill who have identified the steps by which a cell removes RNA from the cytoplasm.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
Cardiovascular disease is the leading cause of death globally and a tremendous burden on the healthcare system. Better detection of hardening or clogging of arteries and other blood vessels before symptoms occur is needed.
› Verified 3 days ago
| Entity Name | Bone & Joint Clinic Of Baton Rouge, Inc A Professional Medical Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306835079 PECOS PAC ID: 3779478615 Enrollment ID: O20070425000686 |
News Archive
Talecris Biotherapeutics announced today the Canadian launch of PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human])(A1PI), a more concentrated and purified formulation of PROLASTIN®, the only approved alpha1-augmentation therapy in Canada for more than 20 years. PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting the infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min.
RNA encodes the proteins that play a key role in cellular reproduction, but the manner in which cells regulate its removal once these proteins are synthesized remains a mystery. One piece of this mystery has been solved as researchers at the University of North Carolina at Chapel Hill who have identified the steps by which a cell removes RNA from the cytoplasm.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
Cardiovascular disease is the leading cause of death globally and a tremendous burden on the healthcare system. Better detection of hardening or clogging of arteries and other blood vessels before symptoms occur is needed.
› Verified 3 days ago
| Entity Name | The Hospital Service District Of West Feliciana Parish Louisiana |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1164497533 PECOS PAC ID: 3173512548 Enrollment ID: O20141110000718 |
News Archive
Talecris Biotherapeutics announced today the Canadian launch of PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human])(A1PI), a more concentrated and purified formulation of PROLASTIN®, the only approved alpha1-augmentation therapy in Canada for more than 20 years. PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting the infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min.
RNA encodes the proteins that play a key role in cellular reproduction, but the manner in which cells regulate its removal once these proteins are synthesized remains a mystery. One piece of this mystery has been solved as researchers at the University of North Carolina at Chapel Hill who have identified the steps by which a cell removes RNA from the cytoplasm.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
Cardiovascular disease is the leading cause of death globally and a tremendous burden on the healthcare system. Better detection of hardening or clogging of arteries and other blood vessels before symptoms occur is needed.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Tyson Garon, MD Po Box 98035, Baton Rouge, LA 70898-9035 Ph: (225) 819-5016 | Mark Tyson Garon, MD 7301 Hennessy Blvd Ste 200, Department Of Orthopedics, Baton Rouge, LA 70808-4794 Ph: (225) 766-0050 |
News Archive
Talecris Biotherapeutics announced today the Canadian launch of PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human])(A1PI), a more concentrated and purified formulation of PROLASTIN®, the only approved alpha1-augmentation therapy in Canada for more than 20 years. PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting the infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min.
RNA encodes the proteins that play a key role in cellular reproduction, but the manner in which cells regulate its removal once these proteins are synthesized remains a mystery. One piece of this mystery has been solved as researchers at the University of North Carolina at Chapel Hill who have identified the steps by which a cell removes RNA from the cytoplasm.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
Cardiovascular disease is the leading cause of death globally and a tremendous burden on the healthcare system. Better detection of hardening or clogging of arteries and other blood vessels before symptoms occur is needed.
› Verified 3 days ago
Kenneth C. Cranor, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 5408 Flanders Dr, Baton Rouge, LA 70808 Phone: 225-769-0173 Fax: 225-769-1730 | |
Dr. Michael R Robichaux Jr., MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8080 Bluebonnet Blvd, Suite 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7984 | |
Dr. Barry Michael Rills, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 8080 Bluebonnet Blvd, Suite 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7984 | |
Dr. John Marshall Whatley, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8080 Bluebonnet Blvd Ste 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7980 | |
John F Loupe, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 2223 Quail Run Ste G, Baton Rouge, LA 70808 Phone: 225-406-7222 Fax: 225-286-2964 | |
Tabitha Lynn Franklin, CST/CSFA Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 8080 Bluebonnet Blvd Ste 1000, Baton Rouge, LA 70810 Phone: 225-408-6633 Fax: 225-408-7965 | |
Timothy Charles Bowlin, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8080 Bluebonnet Blvd, Suite 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7980 |